Neurocrine Biosciences ($NBIX) announced an update on their ongoing clinical study. Neurocrine Biosciences (NBIX) has initiated a Phase 2 clinical ...
Maridebart cafraglutide showed up to 19.9% weight loss in obesity and 17% in obesity-diabetes patients in a phase 2 trial. The drug's 21-day half-life, combining GLP-1 receptor agonism and GIP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback